240 related articles for article (PubMed ID: 33311588)
1. A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma.
Shapiro GI; LoRusso P; Dowlati A; T Do K; Jacobson CA; Vaishampayan U; Weise A; Caimi PF; Eder JP; French CA; Labriola-Tompkins E; Boisserie F; Pierceall WE; Zhi J; Passe S; DeMario M; Kornacker M; Armand P
Br J Cancer; 2021 Feb; 124(4):744-753. PubMed ID: 33311588
[TBL] [Abstract][Full Text] [Related]
2. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.
Dickinson M; Briones J; Herrera AF; González-Barca E; Ghosh N; Cordoba R; Rutherford SC; Bournazou E; Labriola-Tompkins E; Franjkovic I; Chesne E; Brouwer-Visser J; Lechner K; Brennan B; Nüesch E; DeMario M; Rüttinger D; Kornacker M; Hutchings M
Blood Adv; 2021 Nov; 5(22):4762-4770. PubMed ID: 34581757
[TBL] [Abstract][Full Text] [Related]
3. A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome.
Roboz GJ; Desai P; Lee S; Ritchie EK; Winer ES; DeMario M; Brennan B; Nüesch E; Chesne E; Brennan L; Lechner K; Kornacker M; DeAngelo DJ
Leuk Lymphoma; 2021 Jul; 62(7):1740-1748. PubMed ID: 33586590
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.
Trabucco SE; Gerstein RM; Evens AM; Bradner JE; Shultz LD; Greiner DL; Zhang H
Clin Cancer Res; 2015 Jan; 21(1):113-22. PubMed ID: 25009295
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma.
Moreno V; Sepulveda JM; Vieito M; Hernández-Guerrero T; Doger B; Saavedra O; Ferrero O; Sarmiento R; Arias M; De Alvaro J; Di Martino J; Zuraek M; Sanchez-Pérez T; Aronchik I; Filvaroff EH; Lamba M; Hanna B; Nikolova Z; Braña I
Ann Oncol; 2020 Jun; 31(6):780-788. PubMed ID: 32240793
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
Friedberg JW; Mahadevan D; Cebula E; Persky D; Lossos I; Agarwal AB; Jung J; Burack R; Zhou X; Leonard EJ; Fingert H; Danaee H; Bernstein SH
J Clin Oncol; 2014 Jan; 32(1):44-50. PubMed ID: 24043741
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.
Piha-Paul SA; Hann CL; French CA; Cousin S; Braña I; Cassier PA; Moreno V; de Bono JS; Harward SD; Ferron-Brady G; Barbash O; Wyce A; Wu Y; Horner T; Annan M; Parr NJ; Prinjha RK; Carpenter CL; Hilton J; Hong DS; Haas NB; Markowski MC; Dhar A; O'Dwyer PJ; Shapiro GI
JNCI Cancer Spectr; 2020 Apr; 4(2):pkz093. PubMed ID: 32328561
[TBL] [Abstract][Full Text] [Related]
8. First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
Ameratunga M; Braña I; Bono P; Postel-Vinay S; Plummer R; Aspegren J; Korjamo T; Snapir A; de Bono JS
Br J Cancer; 2020 Dec; 123(12):1730-1736. PubMed ID: 32989226
[TBL] [Abstract][Full Text] [Related]
9. Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.
Pearson AD; DuBois SG; Buenger V; Kieran M; Stegmaier K; Bandopadhayay P; Bennett K; Bourdeaut F; Brown PA; Chesler L; Clymer J; Fox E; French CA; Germovsek E; Giles FJ; Bender JG; Hattersley MM; Ludwinski D; Luptakova K; Maris J; McDonough J; Nikolova Z; Smith M; Tsiatis AC; Vibhakar R; Weiner S; Yi JS; Zheng F; Vassal G
Eur J Cancer; 2021 Mar; 146():115-124. PubMed ID: 33601323
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
11. Bromodomain inhibition in diffuse large B-cell lymphoma--giving MYC a brake.
Mottok A; Gascoyne RD
Clin Cancer Res; 2015 Jan; 21(1):4-6. PubMed ID: 25165099
[TBL] [Abstract][Full Text] [Related]
12. Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
Cousin S; Blay JY; Garcia IB; de Bono JS; Le Tourneau C; Moreno V; Trigo J; Hann CL; Azad AA; Im SA; Cassier PA; French CA; Italiano A; Keedy VL; Plummer R; Sablin MP; Hemming ML; Ferron-Brady G; Wyce A; Khaled A; Datta A; Foley SW; McCabe MT; Wu Y; Horner T; Kremer BE; Dhar A; O'Dwyer PJ; Shapiro GI; Piha-Paul SA
Int J Cancer; 2022 Mar; 150(6):993-1006. PubMed ID: 34724226
[TBL] [Abstract][Full Text] [Related]
13. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.
Mahadevan D; Chiorean EG; Harris WB; Von Hoff DD; Stejskal-Barnett A; Qi W; Anthony SP; Younger AE; Rensvold DM; Cordova F; Shelton CF; Becker MD; Garlich JR; Durden DL; Ramanathan RK
Eur J Cancer; 2012 Dec; 48(18):3319-27. PubMed ID: 22921184
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
Jung M; Kim S; Lee JK; Yoon SO; Park HS; Hong SW; Park WS; Kim JE; Kim J; Keam B; Kim HJ; Kang HJ; Kim DW; Jung KC; Kim YT; Heo DS; Kim TM; Jeon YK
Oncologist; 2019 Aug; 24(8):e740-e748. PubMed ID: 30696721
[TBL] [Abstract][Full Text] [Related]
15. Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.
Cervantes A; Elez E; Roda D; Ecsedy J; Macarulla T; Venkatakrishnan K; Roselló S; Andreu J; Jung J; Sanchis-Garcia JM; Piera A; Blasco I; Maños L; Pérez-Fidalgo JA; Fingert H; Baselga J; Tabernero J
Clin Cancer Res; 2012 Sep; 18(17):4764-74. PubMed ID: 22753585
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations.
Dees EC; Cohen RB; von Mehren M; Stinchcombe TE; Liu H; Venkatakrishnan K; Manfredi M; Fingert H; Burris HA; Infante JR
Clin Cancer Res; 2012 Sep; 18(17):4775-84. PubMed ID: 22767670
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
[TBL] [Abstract][Full Text] [Related]
18. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.
Ceribelli M; Kelly PN; Shaffer AL; Wright GW; Xiao W; Yang Y; Mathews Griner LA; Guha R; Shinn P; Keller JM; Liu D; Patel PR; Ferrer M; Joshi S; Nerle S; Sandy P; Normant E; Thomas CJ; Staudt LM
Proc Natl Acad Sci U S A; 2014 Aug; 111(31):11365-70. PubMed ID: 25049379
[TBL] [Abstract][Full Text] [Related]
19. First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity.
Postel-Vinay S; Herbschleb K; Massard C; Woodcock V; Soria JC; Walter AO; Ewerton F; Poelman M; Benson N; Ocker M; Wilkinson G; Middleton M
Eur J Cancer; 2019 Mar; 109():103-110. PubMed ID: 30711772
[TBL] [Abstract][Full Text] [Related]
20. Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study.
Takahashi S; Fujiwara Y; Nakano K; Shimizu T; Tomomatsu J; Koyama T; Ogura M; Tachibana M; Kakurai Y; Yamashita T; Sakajiri S; Yamamoto N
Cancer Sci; 2021 Jun; 112(6):2361-2370. PubMed ID: 33686772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
